BR112018009851A2 - polipeptídios mutados de hev e uso dos mesmos para a contagem de anticorpos anti-hev - Google Patents

polipeptídios mutados de hev e uso dos mesmos para a contagem de anticorpos anti-hev

Info

Publication number
BR112018009851A2
BR112018009851A2 BR112018009851A BR112018009851A BR112018009851A2 BR 112018009851 A2 BR112018009851 A2 BR 112018009851A2 BR 112018009851 A BR112018009851 A BR 112018009851A BR 112018009851 A BR112018009851 A BR 112018009851A BR 112018009851 A2 BR112018009851 A2 BR 112018009851A2
Authority
BR
Brazil
Prior art keywords
hev
orf2 protein
amino acid
mutated
positions
Prior art date
Application number
BR112018009851A
Other languages
English (en)
Other versions
BR112018009851B1 (pt
Inventor
Luciani Françoise
Goutagny Nadège
Daniel Soizic
Ataman-Onal Yasemin
Original Assignee
Biomerieux Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux Sa filed Critical Biomerieux Sa
Publication of BR112018009851A2 publication Critical patent/BR112018009851A2/pt
Publication of BR112018009851B1 publication Critical patent/BR112018009851B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/085Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • C07K14/10Hepatitis A virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/28011Hepeviridae
    • C12N2770/28111Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção refere-se a polipeptídio da proteína p-orf2 do vírus da hepatite e compreendendo pelo menos a sequência de aminoácidos 394-660, numerados em relação a uma proteína p-orf2 de 660 aminoácidos, na qual as três cisteínas nas posições 627, 630 e 638 foram mutadas ou, para uma proteína p-orf2 de comprimento diferente, pelo menos a sequência de aminoácidos correspondente aos aminoácidos 394-660 da proteína p-orf2 de 660 aminoácidos, na qual as três cisteínas situadas nas três posições correspondentes às posições 627, 630 e 638 da proteína p-orf2 de 660 aminoácidos foram mutadas. ela também se refere a processos de determinação da presença de resposta humoral ou da taxa de anticorpos direcionados contra a proteína p-orf2 utilizando esses polipeptídios, assim como seu uso no contexto de uma infecção pelo vírus da hepatite e. sem desenhos.
BR112018009851-5A 2015-11-30 2016-11-29 Polipeptídio da proteína p-orf2 do vírus da hepatite e, processos in vitro de determinação por imunoensaio: da presença de uma resposta mediada por anticorpos direcionada contra a proteína p-orf2, e da taxa de anticorpos direcionados contra a proteína p-orf-2, seus usos, e kit BR112018009851B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1561596 2015-11-30
FR1561596A FR3044312B1 (fr) 2015-11-30 2015-11-30 Polypeptides mutes de hev et leur utilisation pour le dosage d'anticorps anti-hev
PCT/FR2016/053127 WO2017093649A1 (fr) 2015-11-30 2016-11-29 Polypeptides mutés de hev et leur utilisation pour le dosage d'anticorps anti-hev

Publications (2)

Publication Number Publication Date
BR112018009851A2 true BR112018009851A2 (pt) 2018-11-13
BR112018009851B1 BR112018009851B1 (pt) 2025-06-17

Family

ID=

Also Published As

Publication number Publication date
FR3044312B1 (fr) 2017-12-08
FR3044312A1 (fr) 2017-06-02
WO2017093649A1 (fr) 2017-06-08
ES2912907T3 (es) 2022-05-30
US10408841B2 (en) 2019-09-10
US20180328929A1 (en) 2018-11-15
CN108473540A (zh) 2018-08-31
EP3383887A1 (fr) 2018-10-10
KR20180083941A (ko) 2018-07-23
EP3383887B1 (fr) 2022-03-16
CN108473540B (zh) 2022-07-29

Similar Documents

Publication Publication Date Title
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
BR112018073761A2 (pt) proteínas de ligação ao cd3 de fragmento variável de cadeia única
BR112016028066A2 (pt) composição de vacina; idessuis; ridessuis; anticorpo; composição parenteral; uso de uma proteína idessuis ou ridessuis; e célula hospedeira
MD4655B1 (ro) Virusurile bolii de Newcastle şi utilizarea acestora
MY196882A (en) Recombinant binding proteins and their use
BR112016030965A2 (pt) Composições de veículo-anticorpo e métodos de fabricação e uso das mesmas
MA41313A (fr) Anticorps de liaison de la protéine april modifiés
MX2017008643A (es) Proteina de fusion que comprende un dominio de union a ligando de factor de crecimiento endotelial vascular (vegf) y factor de crecimiento derivado de plaquetas (pdgf).
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
BR112017009764A2 (pt) anticorpos biespecíficos e métodos de uso em oftalmologia
IL292625A (en) Viruses with modified capsid proteins
BR112017001463A2 (pt) célula hospedeira melhorada para produzir proteínas
MX383506B (es) Parvovirus porcino.
DK3146042T3 (da) Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
BR112016024462A2 (pt) ?métodos para a preparação de uma proteína, proteína heteromultimérica, composição e célula hospedeira?
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
BR112015004629A2 (pt) polipeptídeos de clostridium difficile como vacinas
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
MX373809B (es) Virus de la viruela porcina recombinante y vacunas.
EP3404039A4 (en) RECOMBINANT PICP PROTEIN AND METHOD FOR PRODUCING SPECIALLY BINDING ANTIBODIES THEREOF
WO2013138259A3 (en) Polypeptides for treating and/or limiting influenza infection
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
MX2018002616A (es) Proteina de fusion.
BR112018009851A2 (pt) polipeptídios mutados de hev e uso dos mesmos para a contagem de anticorpos anti-hev
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/11/2016, OBSERVADAS AS CONDICOES LEGAIS